{"id":"hetrombopag","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["SHR8735","Hetrombopag Olamine","Hetrombopag Olamine Tablets"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=hetrombopag","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:24:16.131756+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:24:44.837887+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:24:21.959854+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=hetrombopag","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:24:37.439171+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thrombopoietin receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:24:38.481158+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297764/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:24:38.133004+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Hetrombopag, developed by Sun Yat-sen University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.","ecosystem":[],"_scrapedAt":"2026-03-27T23:47:44.477Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:24:44.837997+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07492693","phase":"PHASE2","title":"Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-10-01","conditions":"Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors","enrollment":40},{"nctId":"NCT07408648","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-04-15","conditions":"Chemotherapy Induced Thrombocytopenia","enrollment":244},{"nctId":"NCT07334093","phase":"PHASE2","title":"A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-31","conditions":"Cancer Therapy-induced Thrombocytopenia (CTIT)","enrollment":204},{"nctId":"NCT07286032","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02","conditions":"Patients With Chemotherapy-Induced Thrombocytopenia","enrollment":150},{"nctId":"NCT06818916","phase":"NA","title":"Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2024-06-30","conditions":"Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation","enrollment":30},{"nctId":"NCT07252375","phase":"PHASE2","title":"A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-30","conditions":"Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia","enrollment":35},{"nctId":"NCT07243418","phase":"PHASE2","title":"Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-30","conditions":"CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer","enrollment":72},{"nctId":"NCT05660785","phase":"PHASE2","title":"Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-01","conditions":"Non Severe Aplastic Anemia, Untreated","enrollment":54},{"nctId":"NCT07101627","phase":"PHASE2","title":"A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-01","conditions":"Lung Cancer","enrollment":149},{"nctId":"NCT04737850","phase":"PHASE3","title":"Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-29","conditions":"Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT05394285","phase":"PHASE2","title":"A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2022-08-19","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT07010237","phase":"PHASE2","title":"Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-02-01","conditions":"Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment","enrollment":65},{"nctId":"NCT07003269","phase":"","title":"Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT","status":"ENROLLING_BY_INVITATION","sponsor":"Haikou Affiliated Hospital of Central South University Xiangya School of Medicine","startDate":"2024-09-01","conditions":"Thalassemia in Children","enrollment":30},{"nctId":"NCT03976882","phase":"PHASE3","title":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-11-06","conditions":"Chemotherapy-Induced Thrombocytopenia","enrollment":129},{"nctId":"NCT05864014","phase":"PHASE3","title":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-04-25","conditions":"Chemotherapy-Induced Thrombocytopenia","enrollment":213},{"nctId":"NCT03825744","phase":"PHASE3","title":"Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-05","conditions":"Severe Aplastic Anemia","enrollment":240},{"nctId":"NCT04961710","phase":"PHASE3","title":"Extension Study of Hetrombopag in Severe Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-09-19","conditions":"Treatment-naive Severe Aplastic Anemia","enrollment":157},{"nctId":"NCT06562738","phase":"PHASE4","title":"Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia","status":"RECRUITING","sponsor":"The Third People's Hospital of Chengdu","startDate":"2024-06-01","conditions":"Thrombocytopenia","enrollment":55},{"nctId":"NCT05718856","phase":"PHASE4","title":"TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-23","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":166},{"nctId":"NCT04915482","phase":"PHASE2, PHASE3","title":"TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-06-06","conditions":"Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome","enrollment":94},{"nctId":"NCT06478537","phase":"PHASE2","title":"TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-06-20","conditions":"Immune Thrombocytopenia","enrollment":56},{"nctId":"NCT06433830","phase":"PHASE2","title":"Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2022-05-10","conditions":"Thrombocytopenia, Radiotherapy Side Effect","enrollment":50},{"nctId":"NCT05442632","phase":"PHASE2","title":"Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-07-25","conditions":"Hepatopathy","enrollment":96},{"nctId":"NCT05088655","phase":"PHASE1","title":"A Bioequivalence Study of Hetrombopag in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-06-25","conditions":"Sever Aplastic Anaemia","enrollment":58},{"nctId":"NCT06099925","phase":"PHASE2","title":"The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-10-16","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":48},{"nctId":"NCT05261646","phase":"PHASE3","title":"A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia","status":"WITHDRAWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-04-15","conditions":"Chemotherapy-Induced Thrombocytopenia","enrollment":""},{"nctId":"NCT05943691","phase":"PHASE2","title":"High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-09-15","conditions":"ITP - Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT06036966","phase":"PHASE2","title":"The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-09-16","conditions":"Thrombocytopenia","enrollment":34},{"nctId":"NCT05969158","phase":"PHASE2","title":"Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-09-04","conditions":"Chemotherapy-Induced Thrombocytopenia","enrollment":90},{"nctId":"NCT05944211","phase":"PHASE2","title":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-07","conditions":"Chemotherapy-Induced Thrombocytopenia","enrollment":72},{"nctId":"NCT05727917","phase":"NA","title":"Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-01-01","conditions":"Hematological Disease, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":78},{"nctId":"NCT05575986","phase":"PHASE4","title":"Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-10","conditions":"Malignant Tumors of the Digestive System, Trombocitopenia","enrollment":40},{"nctId":"NCT03222843","phase":"PHASE3","title":"Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-06-30","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":424},{"nctId":"NCT03557099","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-06-20","conditions":"Severe Aplastic Anemia","enrollment":55},{"nctId":"NCT05392647","phase":"PHASE2","title":"Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2022-07-01","conditions":"Myelodysplastic Syndromes","enrollment":28},{"nctId":"NCT05333861","phase":"","title":"An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-05-01","conditions":"Primary Immune Thrombocytopenia, Aplastic Anemia","enrollment":1150},{"nctId":"NCT05311930","phase":"PHASE4","title":"Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-05-01","conditions":"Primary Immune Thrombocytopenia","enrollment":69},{"nctId":"NCT05088642","phase":"PHASE1","title":"A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-28","conditions":"Sever Aplastic Anaemia","enrollment":24},{"nctId":"NCT05088174","phase":"PHASE1","title":"A Trial of Hetrombopag in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-03","conditions":"Sever Aplastic Anaemia","enrollment":26},{"nctId":"NCT05088343","phase":"PHASE1","title":"Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-07","conditions":"Healthy Subjects","enrollment":14},{"nctId":"NCT05024877","phase":"PHASE2, PHASE3","title":"Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"MDS","enrollment":50},{"nctId":"NCT05018936","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"Aplastic Anemia, Drug Effect","enrollment":40},{"nctId":"NCT04688008","phase":"PHASE1","title":"Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-18","conditions":"Bioavailability Study","enrollment":58},{"nctId":"NCT03977805","phase":"PHASE1","title":"Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-05-25","conditions":"Healthy","enrollment":6},{"nctId":"NCT03603132","phase":"PHASE1","title":"A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-07-14","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT02614846","phase":"PHASE1","title":"Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-08","conditions":"Chronic Idiopathic Thrombocytopenic Purpura","enrollment":29},{"nctId":"NCT02409394","phase":"PHASE1","title":"Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-03","conditions":"Healthy","enrollment":12},{"nctId":"NCT01830660","phase":"PHASE1","title":"A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-04","conditions":"Healthy","enrollment":96},{"nctId":"NCT02403440","phase":"PHASE1","title":"A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-04","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"MYELOSUPPRESSION"},{"count":3,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"CARDIAC ARREST"},{"count":2,"reaction":"COMA"},{"count":2,"reaction":"DISSEMINATED INTRAVASCULAR COAGULATION"},{"count":2,"reaction":"DISSEMINATED VARICELLA ZOSTER VIRUS INFECTION"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"HEPATIC FAILURE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL4297764"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":71,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"hetrombopag","genericName":"hetrombopag","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:24:44.837997+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}